A Follow-up Study to Evaluate the Safety of ALLO-ASC-CD in ALLO-ASC-CD-101 Clinical Trial
Recruiting · NCT03183661 · Observational (researchers observe without assigning treatment) · Lead sponsor: Anterogen Co., Ltd.
View the official record on ClinicalTrials.gov →Interventions studied
ALLO-ASC-CD
What this trial is about
This is an open-label follow up study to evaluate the safety for the subjects with ALLO-ASC-CD injection in phase 1 clinical trial (ALLO-ASC-CD-101) for 36 months.
Who can take part
Age range
18 Years to 65 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Subjects who are injected with ALLO-ASC-CD in phase 1 clinical trial of ALLO-ASC-CD-101.
- Subjects who are able to give written informed consent prior to study start and to comply with the study requirements.
Exclusion criteria
- \. Subjects who are considered not suitable for the study by the principal investigator.
Where it is running
2 locations listed.
- Seoul National University Hospital - Seoul, South Korea
- Severance Hospital - Seoul, South Korea